Biden Administration Launches Office for Long COVID Research
TUESDAY, Aug. 1, 2023 (HealthDay News) -- As Americans continue to grapple with the effects of long COVID, the Biden administration on Monday announced the creation of a new office focused on research about the condition that will be part of the U.S. Department of Health and Human Services.
The Office of Long COVID Research and Practice will lead the U.S. response to long COVID, which includes trials that have already been launched, the HHS said in an agency news release.
"As our nation continues to make strides in combating COVID-19, it is crucial that we address the impact of long COVID and provide resources to those in need," said HHS Secretary Xavier Becerra. "Last year, President Biden called on HHS to coordinate the response to long COVID. The official establishment of the Long COVID Coordinating office and the launch of the RECOVER clinical trials solidifies this issue as an ongoing priority."
The $1.15 billion RECOVER research program is meant to better understand, treat, and prevent long COVID; as many as 23 million Americans have developed the condition, according to HHS estimates.
Research has identified 12 possible symptoms of long COVID, including worsening of health after mental or physical activity, fatigue, brain fog and dizziness, changes in taste or smell, thirst, and changes in sexual desire or capacity. It can also include gastrointestinal symptoms, heart palpitations, chronic cough, chest pain, and abnormal movements. These are among more than 200 symptoms that have been associated with long COVID.
"The Office of Long COVID Research and Practice will enhance efforts being undertaken across the U.S. government to improve the lives of those who continue to experience the long-term impacts of the worst public health crisis in a century," said HHS Assistant Secretary of Health Adm. Rachel Levine, M.D., who will lead the new research effort.
Related Posts
Eliminar el desorden quizá no ayude a las personas con demencia
LUNES, 6 de diciembre de 2021 (HealthDay News) -- Quizás piense que ordenar las...
Extra Parenteral Amino Acids No Benefit for Extremely Preterm Infants
THURSDAY, Nov. 3, 2022 (HealthDay News) -- For infants with extremely low...
La vacuna contra la COVID de tres dosis de Pfizer provoca una fuerte respuesta en los niños más pequeños
LUNES, 23 de mayo de 2022 (HealthDay News) -- Pfizer/BioNTech afirma que un...
Merck pedirá a la FDA la aprobación de emergencia de su nueva pastilla antiviral contra la COVID
VIERNES, 1 de octubre de 2021 (HealthDay News) -- La gigante farmacéutica Merck...